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Abstract 
Background: Studies in Southeast Asia reported a strong relationship between polymorphisms at the propeller 
domain of the Kelch 13 (K13) protein encoded by the Plasmodium falciparum k13 (pfk13) gene and delayed parasite 
clearance after artemisinin treatment. In Africa, P. falciparum remains susceptible and combination therapy regimens 
which include an artemisinin component display good efficacy. Using quantitative real-time PCR (qPCR), sub-micro-
scopic persistence of P. falciparum has previously been reported in one-third of children treated with artemisinin 
combination therapy (ACT) in western Kenya. In this study, further investigation was made to evaluate whether these 
sub-microscopic residual parasites also harbour mutations at the propeller region of pfk13 and whether the muta-
tions, if any, affect treatment outcome.
Methods: The pfk13 propeller domain was genotyped in DNA samples obtained in 2009 from Kenyan children 
treated with artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP). Paired samples at pre-treatment 
(day 0) and day of treatment failure (day 28 or 42) for 32 patients with documented recurrent parasitaemia were avail-
able for genotyping. Additional day 3 DNA samples were available for 10 patients.
Results: No mutation associated with artemisinin resistance in Southeast Asia was observed. Only one DP-treated 
patient harboured a non-synonymous mutation at codon 578 (A578S) of pfk13-propeller gene in the day 0 sample, but 
this allele was replaced by the wild-type (A578) form on day 3 and on the day of recurrent parasitaemia. The mutation 
at amino acid codon 578 showed no association with any phenotype. Polymorphisms in pfk13 were not responsible 
for parasite persistence and gametocyte carriage in the children treated with ACT.
Conclusion: This study contributes to the ongoing surveillance of suspected artemisinin resistance parasites in Africa 
by providing baseline prevalence of k13-propeller mutations in western Kenya with samples collected from a longitu-
dinal study.
Clinical Trials Registration NCT00868465.
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Background
Artemisinin combination therapy (ACT) is widely used 
to treat uncomplicated Plasmodium falciparum malaria 
in endemic areas. Significantly reduced susceptibility to 
artemisinins, characterized by delayed parasite clearance 
in  vivo and enhanced survival of early stage parasites 
in vitro, has been reported in Southeast Asia [1, 2]. Most 
recently, these parasite phenotypes have been associated 
with mutations in the pfk13 gene of P. falciparum, encod-
ing the kelch-domain protein K13 [3]. Further studies 
reported direct evidence of resistance to artemisinin 
using genetic modification of different pfk13 loci [4]. This 
work has led to an operational definition of partial arte-
misinin resistance: ≥5 % of patients carrying K13 resist-
ance-associated mutations, all of whom have been found 
to have either persistent parasitaemia by microscopy on 
day 3, or a parasite clearance half-life of ≥5 h after treat-
ment with ACT or artesunate monotherapy [5].
In Africa, ACT is the first-line anti-malarial treat-
ment and remains efficacious and safe [3, 6]. However, 
resistance to previous generations of anti-malarial 
drugs such as chloroquine, sulfadoxine-pyrimethamine 
(SP) emerged in the 1970s in Southeast Asia and even-
tually spread to the Indian sub-continent and then to 
Africa [7]. It is, therefore, critical that continuous mon-
itoring of the therapeutic response of ACT is carried 
out in endemic areas in order to detect early warning 
signs and effectively track and contain the develop-
ment and spread of artemisinin resistance. Currently, 
delayed clearance of microscopically detectable para-
sites has not been observed in Africa. In addition, there 
are limited data about the in vitro susceptibility of ring 
stage of parasite development against artemisinins as 
well as the presence and prevalence of pfk13 mutations 
[8]. Recently, a cross-sectional survey was carried out 
to determine the prevalence of pfk13 mutations in 14 
sub-Saharan African countries. The study reported the 
absence of mutations that were associated with arte-
misinin resistance in Southeast Asia, with the excep-
tion of codon 543 [9]. In previous study, the presence 
of residual sub-microscopic P. falciparum parasites in 
western Kenyan children on day 3 after ACT treatment 
was reported and this was associated with subsequent 
recrudescence and transmission [10]. In addition, the 
authors have shown in the same Kenyan patient that 
P. falciparum parasites carrying certain genotypes at 
pfmdr1, pfcrt, pfubp1, and pfap2mu genes were found 
to survive more often after ACT treatment at sub-
microscopic level [11]. The aim of this study was to 
investigate whether these sub-microscopic residual 
parasites also harboured mutations at the propel-
ler region of pfk13 and whether the mutations, if any, 
affect treatment outcome.
Methods
DNA samples were previously obtained from filter-paper 
blood spots from children (age 8  months–10  years) 
treated with either artemether–lumefantrine (AL) or 
dihydroartemisinin–piperaquine (DP) in a clinical trial 
carried out in 2009 in Mbita, western Kenya and fully 
described elsewhere [6, 10]. The study was carried out 
5 years after Kenya had officially changed the first line of 
treatment from SP to AL [12]. The protocol was approved 
by the Kenya Medical Research Institute Ethical Review 
Committee and the London School of Hygiene and Trop-
ical Medicine Ethics Committee (reference 5455). Writ-
ten informed consent was obtained from a parent or 
guardian of each participating child. This is an ancillary 
study of pfk13 propeller domain polymorphism in DNA 
samples available from the 2009 study at the following 
time points: for 32 patients with documented recurrent 
parasitaemia, paired samples at day 0 (pretreatment) and 
day of treatment failure (28 or 42, PCR-uncorrected); for 
10 patients, additional day 3 DNA samples (Table 1).
The K13-propeller gene fragment (coordinates 
1726169–1726997 on chromosome 13 of 3D7 isolate 
(PF3D7_1343700) was amplified by nested PCR using 
previously published primers [13]. For the first round of 
PCR, 250  nM primer (Eurofins, Germany), 1X hot fire 
pol® blend master mix (Solis Biodyne, Estonia) and 5 μl 
of DNA in a total volume of 20 µl was run under the fol-
lowing cycling conditions: 95 °C for 15 min then 30 cycles 
at 95 °C for 30 s, 58 °C for 2 min and extension at 72 °C 
for 2  min and final extension at 72  °C for 10  min. For 
the second round of PCR, a total volume of 25 μl made 
of 18.75  μl nuclease free water, 250  nM primer, 1X hot 
fire pol® blend master mix (Solis Biodyne, Estonia) final 
concentration and 5 μl of DNA was run under the follow-
ing cycling conditions: 95 °C for 15 min then 40 cycles at 
95 °C for 30 s, 60 °C for 1 min and extension at 72 °C for 
1 min and final extension at 72 °C for 10 min. A positive 
control (K13_5) with one of the mutations identified in 
Cambodia (provided by D Ménard) was included in every 
experiment.
Polymorphisms at pfk13 were determined by direct 
sequencing of amplicons using ABI BigDye Termina-
tor v3.1 cycling sequencing kit and analysis on an ABI 
3730 sequencer (Applied Biosystems, USA) as described 
previously [11] and chromatogram sequences were ana-
lysed using Geneious v6.1.5 (Biomatters, USA) in com-
parison to pfk13-propeller sequence region of 3D7 isolate 
(PF3D7_134700).
Results
Pfk13 sequences for 32 samples on day 0, seven samples 
on day 3 and 30 samples on day of failure were success-
fully obtained and analysed for sequence variation. Of 
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these 69 sequenced isolates, 68 harboured pfk13 loci 
encoding propeller domains identical to the reference. 
A single DP-treated patient (K1368) harboured a non-
synonymous mutation at codon 578 of pfk13-propeller 
gene in the day 0 sample, but this allele was replaced by 
the wild-type form on day 3 and on the day of recurrent 
parasitaemia (day of failure) (Table 2). The K13-propeller 
sequence was deposited in Gene Bank (accession num-
ber KT261646). To understand the clearance dynamics 
of the mutant parasites in the patient, pfk13 was retro-
spectively sequenced in day 1 and day 2 parasites from 
this individual. Sequence analysis of day 0, day 1 and 
day 2 samples revealed the presence of mutation at 
codon A578S, suggesting that the mutant parasite was 
present 2 days after DP treatment (Figure 1). The treat-
ment outcome and other phenotype and genotype data 
for the patient are found in Table 2. The patient cleared 
parasites as measured by microscopy on day 1 after DP 
treatment and no gametocytes were detected on day 
7. Recurrent parasitaemia was observed on day 42 but 
was classified as new infection after PCR-correction. 
One additional patient carried a synonymous mutation 
at pfk13 codon P553P on day of failure but that was not 
observed on day 0 or day 3.
Table 1 Sample availability for k13 genotyping
Table shows sample which were available for k13 genotyping on different time points. Days 0 and day of fail (days 28 or 42) samples were available for k13 genotyping 
for 32 patients. Of the 32, ten patients had additional samples on day 3 while for patient K3168, additional samples on days 1 and 2 were included retrospectively for 
further k13 genotype analysis
Sample ID D0 D1 D2 D3 D28 D42
K0025 X X
K0344 X X
K0385 X X
K0544 X X
K0598 X X
K0701 X X X
K0719 X X X
K0774 X X
K0804 X X
K0840 X X
K0875 X X
K0881 X X
K1010 X X
K1149 X X X
K1152 X X
K1307 X X
K1348 X X X
K1368 X X X X X
K1438 X X X
K1478 X X
K1521 X X
K1861 X X X
K1917 X X
K1943 X X
K2023 X X
K2024 X X
K3077 X X
K3212 X X X
K3215 X X X
K3404 X X X
K3762 X X
K3801 X X
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Discussion
No evidence was found that artemisinin resistance-asso-
ciated mutations in the pfk13-encoded propeller domain, 
including the major resistance-associated mutation 
C580Y, contribute to ACT treatment failure in Mbita, 
western Kenya. Only one of the 32 patients from this 
longitudinal study had mutation in the propeller region 
of pfk13 gene, despite evidence of parasite persistence in 
over 30  % of children [10]. One patient transiently car-
ried parasites harbouring mutation at codon 578 (A578S) 
on enrolment, and on days 1 and 2 after DP treatment. 
However, these parasites were apparently cleared by DP 
in this individual, and persistent parasites detected at day 
3 and day 42 harboured the wild type A578 allele only. 
However, it is not clear whether the wild type was already 
present on days 0, 1 and 2 but below the detection limit 
of the assay. The importance of multiplicity of infection 
was discussed in detail in previous work and the find-
ings broadly agree with Farnert et  al., who also showed 
that there were genetic changes in samples collected in 
the same patient as short as 6 h apart [10, 14]. In fact, the 
msp1 and msp2 genotyping of the day 0 sample showed 
that the patient was infected with at least three different 
parasite clones. Blood from this patient was presented to 
Anopheles gambiae mosquitoes at day 7 by membrane 
feeding, as reported in previous study, but no infected 
mosquitoes were generated [6].
The A578S polymorphism has previously been reported 
in a cross-sectional study in western Kenya, Kisumu, and 
in four other African countries [9], but the current study 
is the first study to investigate the role of this variant in 
gametocyte carriage and infectiousness to mosquito. These 
findings are consistent with recent published multisite 
studies in Southeast Asia and Africa that showed mutation 
at codon 578 in pfk13 and its lack of association with para-
site clearance half-life in patients treated with ACT [3]. 
In Bangladesh, the mutation at codon 578 has also been 
observed in clinical isolates and using computational mod-
elling, the authors suggested that it has an effect on tertiary 
structure of the protein [15]. Although the parasite har-
bouring the mutant A578S allele was successfully cleared 
by DP, the contribution of piperaquine in clearing these 
parasites is not clear. This polymorphism lies adjacent to 
C580Y, and further in  vivo and in  vitro studies to clarify 
the significance of the A578S mutation are warranted, 
particularly in different genetic backgrounds. Mutations 
in pfcrt, pfmdr1, pfap2mu, and pfubp1 also contribute to 
treatment outcomes after either artemisinin monotherapy 
or ACT treatment [11, 16]. Studies introducing transgenic 
variants of pfk13 and other candidate loci into parasite 
isolates with an African genetic background could clarify 
whether pfk13 mutations or polymorphisms in other genes 
are most relevant in determining artemisinin sensitivity in 
clinical isolates in Africa [4, 17].
The rarity of pfk13 variants in the current small study pre-
cludes from making meaningful assessment of the role of 
A578S and other propeller domain mutations in treatment 
outcomes in Africa. However, it can be confirmed that the 
sub-microscopic clearance phenotype observed in west-
ern Kenya is not directly related to the parasite clearance 
half-life observed in Southeast Asia. The sub-microscopic 
residual parasites have been shown previously to be impor-
tant phenotypes as children harbouring those parasites were 
significantly more likely to be infectious to mosquitoes and 
were more likely to have recurrent asexual parasitaemia on 
day 28 or 42 [10]. Factors associated with the host, drug and 
parasite should be investigated to determine the exact cause 
of the sub-microscopic residual parasites.
This study contributes to the ongoing surveillance of 
suspected artemisinin resistance parasites in Africa by 
providing baseline prevalence of k13-propeller mutations 
in western Kenya with samples collected from a longitu-
dinal study, and thus one of the first to relate genotype 
and phenotype. This information from samples collected 
in 2009 does not reflect the current status of ACT, nor 
the prevalence of k13-propeller mutations now. There-
fore, continuous monitoring of ACT in western Kenya 
and the collation of phenotypic and genotypic data to 
Table 2 Phenotype and genotype outcomes of patient K1368
The patient phenotypic data show typical normal clearing parasites and all samples before treatment show the wild type alleles with the exception of pfk13, where 
the mutant is present at codon 578. However, 3 days after treatment only the wild type of codon 578 was observed. When the pfk13 genotyping on day 3 was 
repeated no amplification was observed
Patient ID Phenotype
D3 Parasite positive Gametocyte D7 positivity Mosquito infection Recurrent parasitaemia PCR correction
K1368 No No No Day 42 New infection
Patient ID Genotype
D0 Pfk13 at 578 D3 Pfk13 at 578 D0 Pfmdr1 at 86/184/1246 Day 0 Pfcrt at 72–76 D0 PfAP2mu S160 N
K1368 S A NFD CVMNK S
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track the emergence and spread of parasites with reduced 
susceptibility to artemisinins is recommend.
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ACT: artemisinin combination therapy; AL: artemether–lumefantrine; DP: 
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